Fiche société
King's College London
Traitements, essais et publications liés.
Traitements2programmes
Essais2liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| AZD0328To test for the first time the potential of a nicotinic agonist on cognitive symptoms in people with mild cognitive impairment (MCI) in Parkinson's disease (PD), referred to as PD-MCI. | Parkinson | Phase 2 | Traitement symptomatique | À vérifier | |
| AZD0328To test for the first time the potential of a nicotinic agonist on cognitive symptoms in people with mild cognitive impairment (MCI) in Parkinson's disease (PD), referred to as PD-MCI. | Parkinson | Phase 2 | Traitement symptomatique | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| AZD0328 | Parkinson | Phase 2 | NCT04810104 | PD-MIND — Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug | WITHDRAWN |
| Riluzole | Parkinson | Phase 3 | NCT00211224 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | TERMINATED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||